Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
Location: Sweden, Lund
Employees: 11-50
Total raised: $939.79K
Founded date: 2009
Investors 1
| Date | Name | Website |
| 20.08.2022 | Flerie Inv... | flerie.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.10.2013 | - | $939.79K | - |
Mentions in press and media 16
| Date | Title | Description |
| 13.12.2021 | Xintela : Letter of Intent - ScanVet Animal Health | Press release December 13, 2021 Xintela and ScanVet Animal Health A/S sign Letter of Intent #Regulatory Xintela announces today that the company has signed a Letter of Intent with the Danish animal health company ScanVet Animal Health A/S. ... |
| 19.11.2021 | Xintela : Interim report January – September | Press release November 19, 2021 Xintela AB Interim report January - September 2021 #Regulatory Summary of the interim report The "Company" or "Xintela" refers to Xintela AB (publ), corporate registration number 556780-34... |
| 04.11.2021 | Update on status and strategy for Xintel | Press release November 4, 2021 Update on status and strategy for Xintela and Targinta #Regulatory Xintela develops stem cell-based treatments with a focus on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subs... |
| 29.10.2021 | New board of directors appointed in Targ | Press release October 29, 2021 New board of directors appointed in Targinta AB #Regulatory Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstran... |
| 12.10.2021 | Xintela : Interview with Professor Folke Sjöberg | Archive Below you will find the collected information on Xintela's press releases, newsletters, diary events, films, media coverage and analyses. August 22, 2016 Xintela today announces that it has settled a dispute and will receive 1,500,0... |
| 30.09.2021 | Xintela : to expand clinical development#Regulatory | Lund, Sweden, September 30 2021 - Xintela announces it will expand clinical development of its stem cell product XSTEM to the next chosen indication venous leg ulcers, the most common type of difficult-to-heal (chronic) wounds in humans. A ... |
| 27.08.2021 | Xintela : Half-year Report 2021August 27, 2021Xintela Half-year Report 2021-01-01 - 2021-06-30#Regulatory | Summary of the half-year report The 'Company' or 'Xintela' refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 1 April - 30 June 2021 • Income amounted to TSEK 0 (0). • Loss before tax totalled TSEK 11... |
| 14.07.2021 | Xintela : backed by its integrin biomarke | Archive Below you will find the collected information on Xintela's press releases, newsletters, diary events, films, media coverage and analyses. August 22, 2016 Xintela today announces that it has settled a dispute and will receive 1,500,0... |
| 21.05.2021 | XINTELA AB (PUBL) Xintela : GMP facility approved May 21, 2021Xintela's GMP facility approved for manufacturing of cell therapy products#Regulatory | Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility. - It is a key achievement from the team t... |
| 20.05.2021 | XINTELA AB (PUBL) Xintela : to develop stem cell therapy#Regulatory | Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM... |
Show more